THERAPEUTICSMD, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.86 USD | -0.53% |
|
0.00% | -17.33% |
| 03-29 | TherapeuticsMD, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 02-06 | Knight Therapeutics Announces Launch of Bijuva in Canada | MT |
| Sales 2022 | 69.96M 5.6B | Sales 2023 | 1.3M 104M | Capitalization | 25.77M 2.06B |
|---|---|---|---|---|---|
| Net income 2022 | 112M 8.97B | Net income 2023 | -10M -801M | EV / Sales 2022 | 0.34 x |
| Net cash position 2022 | 29.31M 2.35B | Net Debt 2023 | 3.68M 294M | EV / Sales 2023 | 22.6 x |
| P/E ratio 2022 |
0.47
x | P/E ratio 2023 |
-2.28
x | Employees | 1 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 96.22% |
More Fundamentals
* Assessed data
More news
More recommendations
| 1 day | -0.53% | ||
| Current month | -18.78% | ||
| 1 month | -17.33% | ||
| 3 months | -18.06% | ||
| 6 months | -7.46% | ||
| Current year | -17.33% |
1 week
1.86
1.93
1 month
1.862.38
Current year
1.862.75
1 year
1.864.73
3 years
1.8669.50
5 years
1.86234.50
10 years
1.86563.00
| Managers | Title | Age | Since |
|---|---|---|---|
Marlan Walker
CEO | Chief Executive Officer | 50 | 31/05/13 |
Joseph Ziegler
DFI | Director of Finance/CFO | - | 16/08/23 |
| Corporate Officer/Principal | - | 28/02/18 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Tommy Thompson
CHM | Chairman | 81 | 15/04/12 |
Cooper Collins
BRD | Director/Board Member | 45 | 27/02/12 |
Gail Naughton
BRD | Director/Board Member | 69 | 19/03/20 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 1.86 | -0.53% | 6,236 |
| 25/04/24 | 1.87 | -2.60% | 10,593 |
| 24/04/24 | 1.92 | +2.13% | 14,863 |
| 23/04/24 | 1.88 | 0.00% | 20,731 |
| 22/04/24 | 1.88 | +1.08% | 19,137 |
Delayed Quote Nasdaq, April 26, 2024 at 09:30 pm
More quotes
TherapeuticsMD, Inc. is a pharmaceutical royalty company, which primarily collects royalties from its licensees. It receives royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. It granted a license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands and assigned its exclusive license to commercialize ANNOVERA to Mayne Pharma. IMVEXXY (estradiol vaginal inserts) pharmaceutical product is for the treatment of moderate-to-severe dyspareunia. BIJUVA pharmaceutical product is a Food and Drug Administration (FDA)-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. ANNOVERA pharmaceutical product is a one-year ring-shaped contraceptive vaginal system (CVS).
Sector
Pharmaceuticals
Calendar
06/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -17.33% | 21.45M | |
| +5.31% | 70.44B | |
| +10.97% | 8.94B | |
| -16.83% | 4.75B | |
| +43.48% | 4.5B | |
| +3.20% | 3.85B | |
| +18.82% | 2.38B | |
| -21.36% | 2.34B | |
| -29.67% | 2.2B | |
| +8.38% | 1.96B |
- Stock Market
- Equities
- TXMD Stock
